Alliance for Pandemic Preparedness

August 4, 2020

Antibody Response against SARS-CoV-2 Spike Protein and Nucleoprotein Evaluated by 4 Automated Immunoassays and 3 ELISAs

Category:

Topic:

  • To measure sensitivity of antibody response against SARS-CoV-2 spike protein and nucleoprotein, 4 automated immunoassays (Roche Abbott, Diasorin, and Snibe) and 3 ELISAs (2 from Euroimmun and Mikrogen) were evaluated using samples from 114 patients with moderate, severe, or critical COVID-19 and 113 pre-pandemic samples. Three weeks post-symptom onset, sensitivity was 100%. Specificity varied from 94.7% to 100%; using a ROC curve to estimate cut-offs corresponding to specificities of 95% and 97.5%, the Roche assay (all immunoglobulins, anti-nucleocapsid) had the highest sensitivity (85% and 81%, respectively). Seroconversion occurred on average 2 days earlier for anti-nucleocapsid assays than the anti-spike assays. Time to IgG seroconversion was similar for critical and non-critical cases.   

Van Elslande et al. (July 2020). Antibody Response against SARS-CoV-2 Spike Protein and Nucleoprotein Evaluated by 4 Automated Immunoassays and 3 ELISAs. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2020.07.038